



PUBLIC CONSULTATION IN PREPARATION OF A LEGAL PROPOSAL TO COMBAT COUNTERFEIT MEDICINES FOR HUMAN USE - KEY IDEAS FOR BETTER PROTECTION OF PATIENTS AGAINST THE RISK OF COUNTERFEIT MEDICINES.

European QP Association Survey Results

1. Do you think that the problem of counterfeit medicines is well addressed in the EU Commission proposal?



2. Are the responsibilities as well as the task to be fulfilled by the Qualified Persons correctly addressed?



Chairman

Dr. Bernd Renger
Director Quality Control
Vetter Pharma-Fertigung GmbH & Co. KG
Germany

Advisory Board Members


Richard Bonner
Qualified Person
UK

Dr. Christopher Burgess
Burgess Consultancy
UK

John Taylor
Medicines & Healthcare Products
Regulatory Agency
UK

Rudolf Völler
GMP Inspectorate Darmstadt
Germany

3. Do you support EMEA's idea to regulate products imported for the purpose for exportation as stringent as products imported to be placed on the Community market?



Chairman

Dr. Bernd Renger
Director Quality Control
Vetter Pharma-Fertigung GmbH & Co. KG
Germany

Advisory Board Members


Richard Bonner
Qualified Person
UK

Dr. Christopher Burgess
Burgess Consultancy
UK


John Taylor
Medicines & Healthcare Products
Regulatory Agency
UK

Rudolf Völler
GMP Inspectorate Darmstadt
Germany

4. Do you think that a system for mandatory GMP inspections at API manufacturers by EU Authorities (in the EU and outside of the EU) should be established?



5. Do you think that the various initiatives (European Commission, EQQM, WHO, OECD, FDA) are coordinated in a sufficient way?



Chairman

Dr. Bernd Renger
Director Quality Control
Vetter Pharma-Fertigung GmbH & Co. KG
Germany

Advisory Board Members

Richard Bonner
Qualified Person
UK

Dr. Christopher Burgess
Burgess Consultancy
UK

John Taylor
Medicines & Healthcare Products
Regulatory Agency
UK

Rudolf Völler
GMP Inspectorate Darmstadt
Germany